Lantheus Medical Imaging Inc. sealed a new purchasing deal with Ottawa-based MDS Nordion for a rare imaging isotope, molybdenum-99.
The Billerica, Mass.-based medical imaging company will begin receiving a weekly supply of Mo-99 when the National Research Universal reactor in Chalk River, Ontario, goes back online, expected the end of July. The contract is good through July 2011.
Mo-99 is the parent isotope of the technetium-99m isotope commonly used in medical imaging. Lantheus needs Mo-99 to fuel its TechneLite generators to make Te-99m. Lantheus vice president of manufacturing and supply chain Bill Dawes said in prepared remarks that the company is committed to helping "stabilize the worldwide Mo-99 shortage." Molybdenum-99 has a half-life of just 2.74 days and is very rare.
Lantheus is in the process of increasing its suppliers for the isotope. In May, the company gained increased access to Mo-99 from the Nuclear Reactor Institute, resulting from a partnership between the Institute for Radioelements in Fleurus, Belgium, and the Rez, Czech Republic-based Nuclear Research Institute.
Last summer Lantheus inked a deal with the Australian Nuclear Science and Technology Organization to receive Mo-99. In March, Mansfield, Mass.-based Covidien plc (NYSE:COV) inked a similar deal with the Polish Institute of Atomic Energy’s Maria reactor.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.